Christopher Greenleaf1, Raina Sinha2, Zachary Cerra1, Peter Chen1, Dilachew Adebo1, Jorge D Salazar1. 1. Children's Heart Institute, Memorial Hermann Hospital, University of Texas Health McGovern Medical School, Houston, Texas, USA. 2. Pediatric and Adult Congenital Cardiac Surgery, Connecticut Children's Medical Center, University of Connecticut, Hartford, Connecticut, USA.
Abstract
BACKGROUND: Borderline small ventricular size or technical issues precluding the use of both ventricles may lead to single ventricle palliation. Fontan complications have led some centers to look for alternatives to the traditional pathway. The objective of this study is to evaluate the essential philosophy and outcomes of a new biventricular (BiV) conversion program. METHODS: The prospectively collected Children's Memorial Hermann Heart Institute Society of Thoracic Surgeon's Database was retrospectively reviewed between July 2017 and July 2020. RESULTS: Thirteen patients met inclusion criteria and underwent BiV conversion during that time. The most frequent diagnosis was malposed great arteries and a ventricular septal defect (VSD) in 4 (31%) patients. Seven (54%) patients were in the first interstage, and 1 (8%) patient had already undergone a Fontan operation before their BiV conversion operation. One or more risk factors for single ventricle palliation (genetic syndrome ≥ moderate atrioventricular valve regurgitation ≥ moderate ventricular dysfunction, presence of signs of Fontan failure) were present in 3 (23%) patients. The median left ventricular end diastolic pressure increased from 5.5 mmHg (4-10 mmHg) to 10 mmHg (6-20 mmHg) postoperatively (p < .05). The right ventricular pressure (RVP) was estimated as less than half systemic in all six patients who were able to be estimated. At a median follow-up of 22.6 months (0.3-36.4 months), 12 (92%) patients are alive. CONCLUSIONS: BiV conversion is feasible with reasonable short-term clinical outcomes. Mortality risk is low, but as seen in other studies, the risk of reintervention is high.
BACKGROUND: Borderline small ventricular size or technical issues precluding the use of both ventricles may lead to single ventricle palliation. Fontan complications have led some centers to look for alternatives to the traditional pathway. The objective of this study is to evaluate the essential philosophy and outcomes of a new biventricular (BiV) conversion program. METHODS: The prospectively collected Children's Memorial Hermann Heart Institute Society of Thoracic Surgeon's Database was retrospectively reviewed between July 2017 and July 2020. RESULTS: Thirteen patients met inclusion criteria and underwent BiV conversion during that time. The most frequent diagnosis was malposed great arteries and a ventricular septal defect (VSD) in 4 (31%) patients. Seven (54%) patients were in the first interstage, and 1 (8%) patient had already undergone a Fontan operation before their BiV conversion operation. One or more risk factors for single ventricle palliation (genetic syndrome ≥ moderate atrioventricular valve regurgitation ≥ moderate ventricular dysfunction, presence of signs of Fontan failure) were present in 3 (23%) patients. The median left ventricular end diastolic pressure increased from 5.5 mmHg (4-10 mmHg) to 10 mmHg (6-20 mmHg) postoperatively (p < .05). The right ventricular pressure (RVP) was estimated as less than half systemic in all six patients who were able to be estimated. At a median follow-up of 22.6 months (0.3-36.4 months), 12 (92%) patients are alive. CONCLUSIONS: BiV conversion is feasible with reasonable short-term clinical outcomes. Mortality risk is low, but as seen in other studies, the risk of reintervention is high.